CARDIOLITE

Google image searchProduct monograph

Active ingredient

tetrakis [cu(mibi)4]bf4, 1 MG/VIAL

DIN: 02328003

Dosage form(s): POWDER FOR SOLUTION

Route(s) of administration: INTRAVENOUS

Schedule: Schedule C

Company: LANTHEUS MI CANADA INC

Date: 04-SEP-2018

ATC:

• V09 — DIAGNOSTIC RADIOPHARMACEUTICALS (ATC, ATC/DDD, )
• V09G — CARDIOVASCULAR SYSTEM (ATC, ATC/DDD)
• V09GX — Other cardiovascular system diagnostic radiopharmaceuticals (ATC, ATC/DDD)

External Links for Cardiolite

Search on Google

• Cardiolite side effects
• Cardiolite dosage
• tetrakis [cu(mibi)4]bf4 side effects
• tetrakis [cu(mibi)4]bf4 dosage